SCHEMBL715562

SCHEMBL715562

CCOC(=O)N1CCC(=O)C(OC)C1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.41
TSHR P16473 1/20 0.40
ALDH1A1 P00352 7/20 0.39
POLB P06746 2/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
PKM P14618 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ABL1 P00519 1/20 0.38
RIN1 Q13671 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
THRB P10828 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL405928 0.88 GAA (0.41) GAATSHRALDH1A1POLBHTT
SCHEMBL31722736 0.87 LMNA (0.47) ALDH1A1POLBHTTSMN1; SMN2LMNA
SCHEMBL15121724 0.84 ALDH1A1 (0.40) GAATSHRALDH1A1POLBHTT
SCHEMBL406005 0.81 GAA (0.39) GAAALDH1A1HTTL3MBTL1MAPT
SCHEMBL938094 0.81 GAA (0.42) GAATSHRALDH1A1POLBHTT
SCHEMBL4374906 0.81 ALDH1A1 (0.45) GAATSHRALDH1A1POLBHTT
SCHEMBL17869460 0.80 NPC1 (0.31) KMT2A
SCHEMBL29959011 0.80 USP2 (0.41) ALDH1A1SMN1; SMN2MAPTKDM4EMEN1
SCHEMBL2397005 0.80 USP2 (0.41) ALDH1A1SMN1; SMN2MAPTKDM4EMEN1
SCHEMBL29957218 0.80 L3MBTL1 (0.41) GAATSHRALDH1A1POLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158010-A1 LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-05-25 US disclosed
US-20230158010-A1 LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-05-25 US disclosed
US-20230158010-A1 LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-05-25 US disclosed
EP-4146625-A1 LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES Takeda Pharmaceutical Company Limited (JP) 2023-03-15 EP disclosed
CN-115515933-A Translumenally acting N- (piperidin-4-yl) benzamide derivatives 武田药品工业株式会社 2022-12-23 CN disclosed
WO-2021225968-A1 LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-11-11 WO disclosed
WO-2021225968-A1 LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-11-11 WO disclosed
EP-2816040-B1 Process for the production of CCR2 receptor antagonists and intermediates thereof CENTREXION THERAPEUTICS CORP (US) 2018-10-17 EP disclosed
EP-2379525-B1 CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD BOEHRINGER INGELHEIM INT (DE) 2015-07-29 EP disclosed
US-9067951-B2 Process and intermediates for the production of CCR2 antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-06-30 US disclosed
US-5674868-A ADMINISTERING TO TREAT DISORDERS SUCH AS ANXIETY, PSYCHOSIS, DEPRESSION, SCHIZOPHRENIA, DURG ABUSE, MIGRAINE, EMESIS AND IRRITABLE BOWEL SYNDROME JANSSEN PHARMACEUTICA N.V. (BE) 1997-10-07 US disclosed
EP-0669919-A1 USE OF DIMETHYLBENZOFURANS AND DIMETHYLBENZOPYRANS AS 5-HT3 ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 1995-09-06 EP disclosed
WO-1994012494-A1 USE OF DIMETHYLBENZOFURANS AND DIMETHYLBENZOPYRANS AS 5-HT3 ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 1994-06-09 WO disclosed
US-5137896-A Useful in treatment of gastrointestinal and psychic disorder; analgesic, antiemetic and antiulcer agent JANSSEN PHARMACEUTICA N.V. (BE) 1992-08-11 US disclosed
US-5057525-A Stimulators of gastrointestinal motility JANSSEN PHARMACEUTICA N.V. (BE) 1991-10-15 US disclosed
US-4962115-A Stimulate motility of gastrointestinal system JANSSEN PHARMACEUTICA N.V. (BE) 1990-10-09 US disclosed
EP-0121972-B1 N-ARYL-ALPHA-AMINO-CARBOXAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 1989-05-24 EP disclosed
EP-0076530-B1 NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1985-12-11 EP disclosed
EP-0121972-A2 N-aryl-alpha-amino-carboxamides JANSSEN PHARMACEUTICA N.V. (BE) 1984-10-17 EP disclosed
EP-0076530-A2 Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1983-04-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158010-A1 LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES HTR4, HTR1A, HTR1D GAA 774/4885TSHR 334/4885ALDH1A1 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.